Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 202
1996 261
1997 351
1998 397
1999 554
2000 640
2001 595
2002 521
2003 814
2004 1096
2005 1151
2006 1026
2007 1006
2008 1053
2009 978
2010 759
2011 899
2012 805
2013 845
2014 836
2015 928
2016 1014
2017 956
2018 902
2019 973
2020 228
Text availability
Article attribute
Article type
Publication date

Search Results

18,211 results
Results by year
Filters applied: . Clear all
Page 1
Investigation of Antigen-Specific T-Cell Receptor Clusters in Human Cancers
Zhang H, et al. Clin Cancer Res 2019. PMID 31831563
PURPOSE: Cancer antigen-specific T cells are key components in antitumor immune response, yet their identification in the tumor microenvironment remains challenging, as most cancer antigens are unknown. ...Integrative analysis on the TCR clusters with multi-omics datasets was performed to profile cancer-associated T cells and to uncover novel cancer antigens. ...
PURPOSE: Cancer antigen-specific T cells are key components in antitumor immune response, yet their identification in the tumor micro …
Use of Circulating Tumor DNA for Cancer Immunotherapy.
Snyder A, et al. Clin Cancer Res 2019 - Review. PMID 31285372
Liquid biopsy offers a versatile, noninvasive opportunity to diagnose, characterize, and monitor disease in patients with cancer. ...
Liquid biopsy offers a versatile, noninvasive opportunity to diagnose, characterize, and monitor disease in patients with cancer. ...
DNA Methylation Markers for Breast Cancer Detection in the Developing World.
Downs BM, et al. Clin Cancer Res 2019. PMID 31300453 Free PMC article.
Twenty-five methylated markers were assayed by Quantitative Multiplex-Methylation-Specific PCR (QM-MSP) to select and test a cancer-specific panel. ...RESULTS: In the discovery cohort, 10 of 25 markers were selected that were highly methylated in breast cancer compared with benign tissues by QM-MSP. ...
Twenty-five methylated markers were assayed by Quantitative Multiplex-Methylation-Specific PCR (QM-MSP) to select and test a cancer-s …
The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance.
Beltran H, et al. Clin Cancer Res 2019. PMID 31363002 Free PMC article.
At present, there is no established therapeutic approach for patients with advanced prostate cancer developing lineage plasticity or small cell neuroendocrine prostate cancer (NEPC) due to knowledge gaps in the underlying biology. ...This Perspective represents a consensus arising from the NCI Workshop on Lineage Plasticity and Androgen Receptor-Independent Prostate Cancer. ...
At present, there is no established therapeutic approach for patients with advanced prostate cancer developing lineage plasticity or …
Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies.
Dylgjeri E, et al. Clin Cancer Res 2019. PMID 31266833 Free PMC article.
DNA-PK is deregulated in selected cancer types and is strongly associated with poor outcome. The underlying mechanisms by which DNA-PK promotes aggressive tumor phenotypes are not well understood. Here, unbiased molecular investigation in clinically relevant tumor models reveals novel functions of DNA-PK in cancer.Experimental Design: DNA-PK function was modulated using both genetic and pharmacologic methods in a series of in vitro models, in vivo xenografts, and patient-derived explants (PDE), and the impact on the downstream signaling and cellular cancer phenotypes was discerned. ...
DNA-PK is deregulated in selected cancer types and is strongly associated with poor outcome. The underlying mechanisms by which DNA-P …
DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway.
Kothari V, et al. Clin Cancer Res 2019. PMID 31266829 Free PMC article.
PURPOSE: Protein kinases are known to play a prominent role in oncogenic progression across multiple cancer subtypes, yet their role in prostate cancer progression remains underexplored. ...CONCLUSIONS: Our data show that DNAPK drives prostate cancer progression through transcriptional regulation of Wnt signaling and is an attractive therapeutic target in aggressive prostate cancer....
PURPOSE: Protein kinases are known to play a prominent role in oncogenic progression across multiple cancer subtypes, yet their role …
Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer.
Liu L, et al. Clin Cancer Res 2019. PMID 31515453
EXPERIMENTAL DESIGN: Non-ICI-treated MSK pan-cancer cohort was used for prognosis analysis. Three independent immunotherapy cohorts, including non-small cell lung cancer (n = 240), skin cutaneous melanoma (n = 174), and mixed cancer (Dana-Farber, n = 98) patients from previous studies, were analyzed for efficacy of ICI therapy. ...Patients with TMB(high)CNA(low) cancer can be an optimal subgroup for ICI therapy....
EXPERIMENTAL DESIGN: Non-ICI-treated MSK pan-cancer cohort was used for prognosis analysis. Three independent immunotherapy cohorts, …
Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel
Willis J, et al. Clin Cancer Res 2019. PMID 31383735
Clinical outcomes for 16 patients with cfDNA MSI-H gastric cancer treated with immunotherapy were evaluated. RESULTS: cfDNA MSI evaluation was shown to have high specificity, precision, and sensitivity, with a limit of detection of 0.1% tumor content. ...Prevalence of cfDNA MSI for major cancer types was consistent with those reported for tissue. Finally, robust clinical activity of immunotherapy treatment was seen in patients with advanced gastric cancer positive for MSI by cfDNA, with 63% (10/16) of patients achieving complete or partial remission with sustained clinical benefit. ...
Clinical outcomes for 16 patients with cfDNA MSI-H gastric cancer treated with immunotherapy were evaluated. RESULTS: cfDNA MSI evalu …
Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies
Parseghian CM, et al. Clin Cancer Res 2019 - Review. PMID 31263029 Free PMC article.
Innate and acquired resistance to anti-EGFR therapy (EGFRi) is a major limitation in the treatment of metastatic colorectal cancer (mCRC). Although RAS genes are the most commonly mutated innate and acquired oncogenes in cancer, there are a number of other mechanisms that limit the effectiveness of EGFRi. ...
Innate and acquired resistance to anti-EGFR therapy (EGFRi) is a major limitation in the treatment of metastatic colorectal cancer (m …
The Immunoscore: Colon Cancer and Beyond.
Angell HK, et al. Clin Cancer Res 2020 - Review. PMID 31413009 Free article.
The Immunoscore may translate to provide a tumor agnostic method to define immune fitness of a given tumor and predict and stratify patients who will benefit from certain therapies (in particular immune therapies) and, ultimately, help save the lives of patients with cancer....
The Immunoscore may translate to provide a tumor agnostic method to define immune fitness of a given tumor and predict and stratify patients …
18,211 results
Jump to page
Feedback